This study investigated the correlation of the presence of circulating tumor cells (CTCs) with clinical characteristics, and the predictive value of CTCs for progression-free survival (PFS) in patients with small-cell lung cancer (SCLC).
Samples were obtained from 42 patients with SCLC before and after the first cycle of chemotherapy. CTCs were quantitated by negative immunomagnetic enrichment and immunocytochemistry using anti-CD45 and anti-pancytokeratin antibodies.
CTCs were positive (≥2) in 76.19% of patients with SCLC and negative in the control group. The presence of CTCs was positively correlated with 6 clinical characteristics. PFS was 6.055 and 10.670 months for patients with ≥2 and <2 CTCs/7.5 mL of blood before chemotherapy; after chemotherapy PFS was 4.862 and 10.535 months, respectively.
This study showed that both baseline CTC numbers and the change in CTC numbers after 1 cycle of chemotherapy are significant prognostic factors of PFS for SCLC.
Tumori 2017; 103(3): 242 - 248
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsYu-Li Wang, Chun-Hua Liu, Jing Li, Xiao-Ping Ma, Ping Gong
- • Accepted on 19/12/2016
- • Available online on 15/02/2017
- • Published in print on 12/05/2017
This article is available as full text PDF.
- Wang, Yu-Li [PubMed] [Google Scholar] 1
- Liu, Chun-Hua [PubMed] [Google Scholar] 2
- Li, Jing [PubMed] [Google Scholar] 3
- Ma, Xiao-Ping [PubMed] [Google Scholar] 3
- Gong, Ping [PubMed] [Google Scholar] 3, * Corresponding Author (email@example.com)
Department of Oncology, Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan - China
Department of Radiation Oncology, People’s Hospital of Xinjiang Uygyr Autonomous Region, Uygyr - China
Department of Oncology, Shihezi University School of Medicine, The First Affiliated Hospital, Shihezi - China
Yu-Li Wang and Chun-Hua Liu are co-first authors of this article.